PMC:2854337 / 24594-25126
Annnotations
{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/2854337","sourcedb":"PMC","sourceid":"2854337","source_url":"https://www.ncbi.nlm.nih.gov/pmc/2854337","text":"Fig. 4 Comparison of the total number of patients (a) and the number treated with antiviral drugs (b) for 90 days with a tracing coverage of 30, 50, and 70%, respectively, and a necessary tracing period of 2, 4, and 6 days, respectively, for the targeted antiviral prophylaxis (TAP) intervention. The squares show the mean value for 100-trial simulations with error bars showing the 95% confidence interval (CI). Grey, light grey, and white squares show the situations for necessary tracing periods of 2, 4, and 6 days, respectively","divisions":[{"label":"label","span":{"begin":0,"end":6}}],"tracks":[]}